Clinical TrialsThe James Cancer Center Columbus, OH
open for enrollment
Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
This study is designed as a multicenter trial, with biological assignment to one of two
study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell
transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may
evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for
researchers, clinicians, patients, and health care underwriters such as Medicare, is the
role of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older
patients with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity
conditioning (RIC) regimens has extended HCT to the care of older patients with acute
myelogenous leukemia (AML) and lymphoma and a number of retrospective and phase II trials
for patients with MDS now show the curative potential of RIC alloHCT in selected patients.
This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to
non-transplant therapies focusing on overall survival. This will be done by having patients
biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care
arm and following them for survival at 3 years.
Are you eligible?
Patients fulfilling the following criteria will be eligible for entry into this
1. Patients with de novo MDS who have, or have previously had, Intermediate-2 or
High risk disease as determined by the International Prognostic Scoring System
(IPSS). Current Intermediate-2 or High risk disease is NOT a requirement.
2. Patients must have an acceptable MDS subtype:
Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory
Refractory anemia with ringed sideroblasts (RARS)
Refractory anemia with excess blasts (RAEB-1)
Refractory anemia with excess blasts (RAEB-2)
Refractory cytopenia with multilineage dysplasia (RCMD)
Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)
Myelodysplastic syndrome (MDS), unclassifiable
3. Patients must have fewer than 20% marrow blasts within 60 days of consent.
4. Patients may have received prior therapy for the treatment of MDS, including but
not limited to: growth factor, transfusion support, immunomodulatory (IMID)
therapy, DNA hypomethylating therapy, or cytotoxic chemotherapy prior to
5. Age 50.0-75.0 years.
6. Karnofsky performance status > 70 or Eastern Cooperative Oncology Group (ECOG) ≤
7. Patients are eligible if no formal unrelated donor search has been activated
prior to date of consent. A formal unrelated donor search begins at the time at
which samples are requested from potential National Marrow Donor Program (NMDP)
donors. Patients who have started a sibling donor search or who have found a
matched sibling donor are eligible.
8. Patients and physicians must be willing to comply with treatment assignment:
1. No intent to proceed with alloHCT using donor sources not specified in this
protocol, including human leukocyte antigen (HLA)-mismatched related or
unrelated donors (< 6/6 HLA related matched or < 8/8 HLA unrelated matched)
or umbilical cord blood unit(s).
2. No intent to use myeloablative conditioning regimens.
3. Intent to proceed with RIC alloHCT if a matched sibling or matched
unrelated donor is identified. There is no requirement as to the timing of
9. Patients must be considered to be suitable RIC alloHCT candidates at the time of
enrollment based on medical history, physical examination, and available
laboratory tests. Specific testing for organ function is not required for
eligibility but, if available, these tests should be used to judge eligibility.
10. Signed informed consent
Patients with the following will be ineligible for registration onto this study:
1. Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to
systemic chemotherapy and/or radiation for malignancy)
2. Current or prior diagnosis of AML
3. Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm
(unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection
(currently taking medication and with progression or no clinical improvement) at
time of enrollment.
4. Patients with prior malignancies, except treated non-melanoma skin cancer or
treated cervical carcinoma in situ. Cancer treated with curative surgery without
chemotherapy/radiation therapy > 5 years previously will be allowed. Cancer
treated with curative surgery < 5 years previously will not be allowed unless
approved by the Protocol Officer or one of the Protocol Chairs.
5. Prior autologous or allogeneic HCT
6. Human Immunodeficiency Virus (HIV) infection
7. Patients of childbearing potential unwilling to use contraceptive techniques
8. Patients with psychosocial conditions that would prevent study compliance